Martins, M. Cristina

Pereira, Paula

Seabra, Catarina

English

Repositório Institucional da Universidade Católica Portuguesa

MEDICINAL BIOTECHNOLOGY4TH MEETING OFBOOK OFABSTRACTS  INVITED SPEAKER 01  Bioengineering applied to gastric cancer management PAULA PARREIRA1,2; CATARINA SEABRA1,2,3*; M. CRISTINA MARTINS1,2,3 1-i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal;  2-INEB, Instituto de Engenharia Biomédica, Universidade do Porto, Portugal;  3- ICBAS, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Portugal;  *Current Affiliation: CBQF- Centro de Biotecnologia e Química Fina, Universidade Católica Portuguesa.   Gastric cancer remains the 5th most common cancer worldwide and the 3rd deadliest. It was recently estimated that 89% of all gastric cancers are linked to Helicobacter pylori infection and, consequently, H. pylori eradication would allow reducing the burden of gastric cancer.The available treatment for H. pylori eradication relies on long time antibiotherapy, which combines at least two antibiotics (clarithromycin plus amoxicillin or metronidazole) and an acid-suppressive drug (e.g. proton pump inhibitor). This therapeutic scheme besides failing in around 20% of the infected patients, also presents several antibiotics-associated secondary effects, such as development of bacterial resistance and dysbiosis (destruction/unbalance of normal healthy gut microbiota). In fact and according to the World Health Organization, H. pylori is one of the 16 antibiotic-resistant bacteria that pose the greatest threat to human health. Therefore it is essential to develop novel antibiotics or strategies to eradicate this gastric pathogen. Over the last years, allying Bioengineering to the use of non-antibiotic derived compounds, our group has developed several innovative strategies aiming H. pylori eradication, with particular emphasis to the use of H. pylori specific glycosylated receptors immobilized onto biomaterials, biomaterials decorated with antimicrobial peptides and lipid nanoparticles loaded with docosahexaenoic acid (DHA). These 3 strategies will be briefly highlighted to demonstrate the Bioengineering potential for gastric infection management and consequently, its role in reducing mortality/morbidity rates linked to gastric cancer.  Keywords: Biomaterials, Bioengineering, New Therapies Development     5

Bioengineering applied to gastric cancer management

https://repositorio.ucp.pt/bitstream/10400.14/29647/1/Bioengineering%20applied%20to%20gastric%20cancer%20management.pdf

Bioengineering applied to gastric cancer management

Abstract

Similar works

Full text

Available Versions

Repositório Institucional da Universidade Católica Portuguesa